Organization (Industry)
Iomedico (Germany)
ClinicalTrials.gov lists Iomedico (Germany) as lead sponsor of 53 trials. It has 29 active development programs and 27 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Iomedico (Germany): 53 lead-sponsored trials and 1 legal-entity registration.
Disease areas (43)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 17 |
| Multiple Myeloma | 8 |
| Neoplasm Metastasis | 8 |
| Carcinoma, Renal Cell | 6 |
| Colorectal Neoplasms | 6 |
Showing 5 of 43 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 5 |
| 2019 | 3 |
| 2018 | 4 |
| 2017 | 4 |
Showing 10 of 21 years.
Recruitment duration, a model prediction: none of the 53 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (29)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| FULVESTRANT | Breast Neoplasms | Phase 2 | 1 |
| Anastrozole | Breast Neoplasms | Phase 2 | 1 |
| Anastrozole | Neoplasm Metastasis | Phase 2 | 1 |
| FULVESTRANT | Neoplasm Metastasis | Phase 2 | 1 |
| Letrozole | Breast Neoplasms | Phase 2 | 1 |
Showing 5 of 29 active programs.
Approved assets (27)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Exemestane | 2 |
| BEVACIZUMAB | 2 |
| "Capecitabine" | 2 |
| EVEROLIMUS | 2 |
| PAZOPANIB | 1 |
Showing 5 of 27 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=25) | 56% on time (n=25) |
Journals published in (40)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| International journal of cancer | 9 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 9 |
| Breast cancer research and treatment | 5 |
| BMC cancer | 4 |
| The New England journal of medicine | 4 |
Showing 5 of 40 journals.
Organization relationships (14)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Chugai Pharma Europe Limited (United Kingdom) | Co sponsors trial with | 1 |
| Oncopeptides (Sweden) | Co sponsors trial with | 1 |
| Pierre Fabre (France) | Co sponsors trial with | 1 |
| Arbeitskreis Klinische Studien | Co sponsors trial with | 1 |
| Bristol Myers Squibb Co | Co sponsors trial with | 1 |
Showing 5 of 14 relationships.
Latest dated events (68)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-02-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 68 events.
Biomarker capability evidence (109)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD38 | Trial sponsor | Named in trial inclusion criteria |
| CISH | Trial sponsor | Named in trial inclusion criteria |
| CISH | Trial sponsor | Named in trial inclusion criteria |
| CISH | Trial sponsor | Named in trial inclusion criteria |
| CYP19A1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 109 evidence rows.
On Scientist.com
Iomedico (Germany) is listed as a research supplier in the Scientist.com network.
Service areas
iOMEDICO provides clinical research services, electronic data capture, and site management.
- Website
- www.iomedico.org
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with iOMEDICO on Scientist.com
For prices, more details, or to contact iOMEDICO, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.